--- title: "Nutra Pharma (NPHC) news: Nasdaq notice" url: "https://aibio.space/companies/nutra-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NPHC Nasdaq notice news: Nutra Pharma files late-filing notice for its June 30, 2026 quarterly report. Nutra Pharma Corp. (OTC: NPHC), United States." --- NPHC Nutra Pharma Corp. OTC · United States # Nutra Pharma (NPHC) news NPHC Nasdaq notice news Distress · 2026-08-14 ## [Nutra Pharma files late-filing notice for its June 30, 2026 quarterly report](https://aibio.space/news/nutra-pharma-files-late-filing-notice-june-30-2026-quarterly-report/) Nutra Pharma filed a Form 12b-25 notice on August 14, 2026, saying its quarterly report for the period ended June 30, 2026 would be late. Its cash at December 31, 2025 was $12,181. ## Latest Nutra Pharma news We have not published a story on Nutra Pharma yet. When there is news, it will appear here. ## Nutra Pharma at a glance - **Ticker**: NPHC - **Listing**: OTC - **Country**: United States - **Cash, Dec 31, 2025**: $29,781 ### Related companies - [IMMUNOTECH LABORATORIES INC](https://aibio.space/companies/immunotech-laboratories/) OTC: IMMB - [Earth Science Tech](https://aibio.space/companies/earth-science-tech/) OTC: ETST - [Artiva Biotherapeutics](https://aibio.space/companies/artiva-biotherapeutics/) NASDAQ: ARTV - [Curanex Pharmaceuticals](https://aibio.space/companies/curanex-pharmaceuticals/) NASDAQ: CURX - [Enveric Biosciences](https://aibio.space/companies/enveric-biosciences/) NASDAQ: ENVB - [MIRA Pharmaceuticals](https://aibio.space/companies/mira-pharmaceuticals/) NASDAQ: MIRA - [ArriVent BioPharma](https://aibio.space/companies/arrivent-biopharma/) NASDAQ: AVBP - [Burzynski Research Institute](https://aibio.space/companies/burzynski-research-institute/) OTC: BZYR ### Also on OTC - [Cannaisseur Group](https://aibio.space/companies/cannaisseur/) TCRG - [Carisma Therapeutics](https://aibio.space/companies/carisma-therapeutics/) CARM - [Trevena](https://aibio.space/companies/trevena/) TRVN - [United Health Products](https://aibio.space/companies/united-health-products/) UEEC - [CASI Pharmaceuticals](https://aibio.space/companies/casi-pharmaceuticals/) CASIF - [Mosaic ImmunoEngineering](https://aibio.space/companies/mosaic-immunoengineering/) CPMV ## What Nutra Pharma does Nutra Pharma Corp. is a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases and pain. It was incorporated in California on February 1, 2000, and launched its first consumer product, Cobroxin, in October 2009. Its current over-the-counter pain relievers include Nyloxin and Nyloxin Extra Strength, which use Asian cobra venom as the active ingredient, along with Pet Pain-Away for cats and dogs, Equine Pain-Away for horses and Luxury Feet for foot pain. The company says it has developed two drug candidates. RPI-78M is aimed at neurological and autoimmune diseases, including Multiple Sclerosis, Adrenomyeloneuropathy, Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis and Myasthenia Gravis. RPI-MN is aimed at viral diseases, including HIV/AIDS and Herpes. The company was granted FDA orphan designation for the treatment of pediatric Multiple Sclerosis in September 2015. It also says it is pursuing its technology as a possible nerve agent countermeasure. The text states that its potential products are subject to FDA approval. | Product or program | What it is | Stage | |---|---|---| | Nyloxin and Nyloxin Extra Strength | OTC topical gel and oral spray for moderate to severe chronic pain | currently marketed | | Pet Pain-Away | OTC pain reliever for cats and dogs | launched December 2014 | | Equine Pain-Away | OTC topical pain reliever for horses | launched October 2019 | | Luxury Feet | OTC pain reliever for foot pain from high heels | launched March 2021 | | RPI-78M | Drug candidate for neurological and autoimmune diseases | subject to FDA approval | | RPI-MN | Drug candidate for viral diseases including HIV/AIDS and herpes | subject to FDA approval | Summarised from the company's [10-K filed May 20, 2026](https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm). ## Nutra Pharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$2.0 million](https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/) | [-$1.3 million](https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/) | | Cash from operations | [-$1.2 million](https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/) | [-$423,959](https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/) | | Cash and equivalents | [$12,181](https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/) | [$36,447](https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/) | | Short-term investments | [$17,600](https://www.sec.gov/Archives/edgar/data/1119643/000149315226039166/) | [$17,600](https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/) | Latest balance sheet, Dec 31, 2025 (10-K): cash and equivalents $12,181, plus short-term investments of $17,600, $29,781 in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Nutra Pharma Has Nutra Pharma received a Nasdaq deficiency notice? Our latest story on this, dated Aug 14, 2026: "Nutra Pharma files late-filing notice for its June 30, 2026 quarterly report". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nutra-pharma-files-late-filing-notice-june-30-2026-quarterly-report/). What is the ticker symbol of Nutra Pharma? Nutra Pharma Corp. trades under the ticker NPHC on OTC. Where is Nutra Pharma listed? Nutra Pharma Corp. is listed on OTC. What is the SEC CIK of Nutra Pharma? The SEC Central Index Key (CIK) for Nutra Pharma Corp. is 1119643. Its filings are on SEC EDGAR. How many shares does Nutra Pharma have outstanding? 7,159,727,214 shares as of 2026-08-19, per the cover page of its 10-Q filed 2026-08-19. Which country or territory is Nutra Pharma listed under? Our directory records Nutra Pharma Corp. under United States. What does Nutra Pharma do? Our directory classifies Nutra Pharma Corp. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline. What is the ISIN of Nutra Pharma? The ISIN recorded for Nutra Pharma Corp. is US67060U2087. Does aibio.space cover Nutra Pharma? aibio.space lists Nutra Pharma Corp. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Nutra Pharma incorporated? SEC records list its state or country of incorporation as CA. What does Nutra Pharma develop? Nutra Pharma Corp. is a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases and pain. It was incorporated in California on February 1, 2000, and launched its first consumer product, Cobroxin, in October 2009. What is Nyloxin and Nyloxin Extra Strength from Nutra Pharma? Nyloxin and Nyloxin Extra Strength: OTC topical gel and oral spray for moderate to severe chronic pain Stage: currently marketed. What is Pet Pain-Away from Nutra Pharma? Pet Pain-Away: OTC pain reliever for cats and dogs Stage: launched December 2014. Is Nutra Pharma profitable? Nutra Pharma Corp. reported a net loss of $2.0 million for the fiscal year ended Dec 31, 2025, and used $1.2 million of cash in operations, per its annual report to the SEC. How much cash does Nutra Pharma have? $29,781 in cash and short-term investments at Dec 31, 2025, per its 10-K. ## Investor discussion: Nutra Pharma Members talk about Nutra Pharma (NPHC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Nutra Pharma, newest first. Each line links the filing it comes from. 1. 2026-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1119643/000149315226038022/formnt10-q.htm) 2. 2025-09-03 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1119643/000164117225026384/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:NPHC on TradingView](https://www.tradingview.com/symbols/OTC-NPHC/). ## SEC filings and registration - **SEC name**: Nutra Pharma Corp - **CIK**: 1119643 - **Industry (SIC)**: Medicinal Chemicals & Botanical Products (2833) - **US tickers**: NPHC (OTC) - **State or country of incorporation**: CA - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 6400 PARK OF COMMERCE BLVD, BOCA RATON, FL, 33487 - **Phone**: (954) 509-0911 - **Shares outstanding**: 7,159,727,214 as of 2026-08-19 (10-Q filed 2026-08-19) - **Former names**: CYBER VITAMIN COM ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1119643/000149315226041208/form8-k.htm) filed 2026-09-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1119643/000149315226039166/form10-q.htm) filed 2026-08-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/1119643/000149315226026420/form10-q.htm) filed 2026-05-29 - [10-K](https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm) filed 2026-05-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/1119643/000149315226015334/form10-q.htm) filed 2026-04-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1119643/000149315226012625/form10-q.htm) filed 2026-03-25 - [10-Q](https://www.sec.gov/Archives/edgar/data/1119643/000149315226009667/form10-q.htm) filed 2026-03-11 - [10-K](https://www.sec.gov/Archives/edgar/data/1119643/000149315226007044/form10-k.htm) filed 2026-02-17 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001119643), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Nutra Pharma Corp. is a public biotech or pharmaceutical company listed on OTC under the ticker NPHC, recorded under United States. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Nutra Pharma Corp. - **Ticker**: NPHC - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceutical profile checked - **ISIN**: US67060U2087 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-NPHC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nutra-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nutra Pharma (NPHC) news: Nasdaq notice", 2026-10-31, https://aibio.space/companies/nutra-pharma/